Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’ phenotypes that rapidly proliferate and kill target cells upon recognition of cognate antigen.
Product Name : NeoTCR-P1
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 04, 2022
Details : NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’ phenotypes that rapidly proliferate and kill target cells upon recognition of cognate antigen.
Product Name : NeoTCR-P1
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 11, 2022
Cellares Adds PACT Pharma to its Early Access Partnership Program
Details : Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount.
Product Name : NeoTCR-P1
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 01, 2021
Details : PACT Pharma Series C proceeds wili expand the scope of its clinical plan to investigate NeoTCR-T cell products targeting multiple neoantigens for a spectrum of solid tumor types.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 01, 2020